Schonfeld Strategic Advisors LLC - CRINETICS PHARMACEUTICALS IN ownership

CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 119 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
Schonfeld Strategic Advisors LLC ownership history of CRINETICS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$8,244,165
+594.7%
277,208
+275.2%
0.06%
+481.8%
Q1 2023$1,186,672
+124.7%
73,890
+297.3%
0.01%
+120.0%
Q4 2021$528,000
+16.6%
18,600
-13.5%
0.01%0.0%
Q3 2021$453,000
+10.2%
21,500
-1.4%
0.01%
+25.0%
Q2 2021$411,00021,8000.00%
Other shareholders
CRINETICS PHARMACEUTICALS IN shareholders Q4 2021
NameSharesValueWeighting ↓
Saturn V Capital Management LP 1,126,579$33,504,45914.02%
New Leaf Venture Partners, L.L.C. 141,000$4,193,3405.38%
First Light Asset Management, LLC 1,583,329$47,088,2044.47%
Paradigm Biocapital Advisors LP 2,178,737$64,795,6384.40%
Bain Capital Life Sciences Investors, LLC 1,275,552$37,934,9164.24%
Altium Capital Management LP 262,000$7,791,8804.06%
5AM Venture Management, LLC 462,286$13,748,3863.96%
MPM BioImpact LLC 479,053$14,247,0363.80%
Affinity Asset Advisors, LLC 450,000$13,383,0003.76%
Opaleye Management Inc. 370,000$11,003,8003.58%
View complete list of CRINETICS PHARMACEUTICALS IN shareholders